• Aucun résultat trouvé

[PDF] Top 20 Total immunotherapy for Hodgkin lymphoma

Has 10000 "Total immunotherapy for Hodgkin lymphoma" found on our website. Below are the top 20 most common "Total immunotherapy for Hodgkin lymphoma".

Total immunotherapy for Hodgkin lymphoma

Total immunotherapy for Hodgkin lymphoma

... Total immunotherapy for Hodgkin lymphoma Roch Houot 1, 2 , Reid W. Merryman 2 , Franck Morschhauser 3 1 Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, ... Voir le document complet

5

Migration Properties Distinguish Tumor Cells of Classical Hodgkin Lymphoma from Anaplastic Large Cell Lymphoma Cells

Migration Properties Distinguish Tumor Cells of Classical Hodgkin Lymphoma from Anaplastic Large Cell Lymphoma Cells

... equilibrated for 1 h in a cell culture ...threshold for the complete picture and local thresholds for each ...A total of 36–56 GFP-Life-Act-labeled cells (all cells per image) were analyzed ... Voir le document complet

17

Early F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab

Early F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab

... guidelines for PET acquisition and ...tool for response assessment and constitute a validation set for previously published data by our group using ... Voir le document complet

27

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

... than for those treated with ...where total body irradiation enhances tumor growth, especially when comparing the therapeutic effect of RICs with agents having low systemic toxicity such as NaCl or unlabeled ... Voir le document complet

20

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†

... Malignant Lymphoma group for PTCL staging since most of them are FDG avid [ 10 , 11 ...value for prognosis prediction at interim and end treatment has been recently investigated [ 12 – 14 ...as ... Voir le document complet

6

Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination

Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination

... 2.2. Calcium Independent Involvement of Orai1 and STIM1 in DLBCL Migration It is well known that SDF-1 is a potent chemoattractant for DLBCL cells. However, the role of Ca 2+ in the pro-migratory effect of SDF-1 ... Voir le document complet

18

Protein Expression Profiles Confirm PASD1 as a Cancer Testis Antigen and a Potential Candidate for Lymphoma Immunotherapy.

Protein Expression Profiles Confirm PASD1 as a Cancer Testis Antigen and a Potential Candidate for Lymphoma Immunotherapy.

... (Hodgkin’s lymphoma), K562 (chronic myeloid leukaemia) and RPMI 8226 (myeloma) lines, whilst cytoplasmic labeling was detected in Karpas 299 (t(2;5) anaplastic large cell lymphoma), SUDHL6, SUDHL10 (both ... Voir le document complet

1

A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

... the total matrix score of each of 119 transcription factor motifs for each of the possible start sites in a window around the SNP and flagging the start positions that surpassed a threshold of 80% of the ... Voir le document complet

11

Hide or defend, the two strategies of lymphoma immune evasion potential implications for immunotherapy

Hide or defend, the two strategies of lymphoma immune evasion potential implications for immunotherapy

... of lymphoma cells (total loss or miss-localization) occurs in 55-75% of diffuse large B-cell lymphoma (DLBCL) 10,11 and 63% of Hodgkin lym- phomas ...negative for MHC-I or β2M have a ... Voir le document complet

14

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study

... mens for first and second ASCT were BEAM (carmustine 300 mg/m 2 /day on day -7; etoposide 200 mg/m 2 /day, day -6 to day -3; cytarabine 200 mg/m 2 /12 h, day -6 to day -3; mel- phalan 140 mg/m 2 /day on day -2) ... Voir le document complet

9

Oncolytic immunotherapy: The new clinical outbreak.

Oncolytic immunotherapy: The new clinical outbreak.

... 2 This last year was productive for the oncolytic viruses (OV) field with numerous advancements. The 9th international conference on oncolytic virus therapeutics, that has been held in Boston, USA, from the 13th ... Voir le document complet

6

Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy

Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy

... targets for personalized medicine, including cancer ...peptides for each patient in a rapid and affordable fashion remains ...needed for patient-specific cancer vaccines to succeed in the ...peptides ... Voir le document complet

12

La maladie de HODGKIN ( A propos de 60 cas )

La maladie de HODGKIN ( A propos de 60 cas )

... Le risque de récidive, souvent dans le même territoire, est de 20 % et est corrélé au stade initial. La MHNPL a été pendant longtemps traitée comme une maladie de Hodgkin classique par des traitements associant ... Voir le document complet

185

Simple model for total cross sections

Simple model for total cross sections

... used for the detection of new physics ...issue for HERA, and will no doubt have a bearing on the extrapolation to the physics at the LHC ...the total cross sections as carefully as possible and to ... Voir le document complet

12

Rationale for stimulator of interferon genes-targeted cancer immunotherapy

Rationale for stimulator of interferon genes-targeted cancer immunotherapy

... responsible for the detection of self-DNA, leading to autoimmunity(25, ...responsible for the detection of cytosolic DNA were unclear until the characterization of STING (Stimulator of Interferon ... Voir le document complet

32

Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.

Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.

... The number and variety of therapeutic interventions capable of preventing diabetes represents an unprece- dented observation in immune pathology. The number of interventions that work in mice with advanced disease, and ... Voir le document complet

14

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.: Anti-AXL mAb for pancreatic cancer immunotherapy

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.: Anti-AXL mAb for pancreatic cancer immunotherapy

... plates for 24h and then switched to serum-free ...mAbs for 1.5h, followed by 200 ng/ml rhGAS6 for 30 ...used for quantifying phosphorylated AXL according to the manufacturer’s ... Voir le document complet

3

Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review.

Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review.

... Immunotherapy for allergic ...allergen‑specifc immunotherapy in IgE mediated allergic diseases—S2 k Guideline of the German Society for Aller gology and Clinical Immunology (DGAKI), the ... Voir le document complet

7

Richter syndrome with plasmablastic lymphoma

Richter syndrome with plasmablastic lymphoma

... History of the disease The patient is a 65 year old man followed for chronic lymphocytic leukemia for 5 years. At the time of diagnosis, he had trisomy 12 and Matutes score of 5. The patient was treated ... Voir le document complet

1

BHS guidelines for the treatment of Burkitt lymphoma

BHS guidelines for the treatment of Burkitt lymphoma

... Burkitt’s lymphoma is a rare but very aggressive non-Hodgkin’s lymphoma characterised by an isolated translocation ...useful for initial staging and to evaluate the chemosensitivity of the tumour ... Voir le document complet

9

Show all 10000 documents...